4.4 Article

Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: A systematic review and meta-analysis

期刊

SCHIZOPHRENIA RESEARCH
卷 123, 期 2-3, 页码 225-233

出版社

ELSEVIER
DOI: 10.1016/j.schres.2010.07.012

关键词

Weight; Cholesterol; Glucose; Individual treatment

资金

  1. Technische Universitat Munchen (HWP II)
  2. German Federal Ministry of Education and Research [FKZ: 01KG 0606, GZ: GFKG01100506]
  3. National Institute of Mental Health, Advanced Center for Intervention and Services Research Center [MH-68580, 1 P01MH68580-01]
  4. CFDA [93.242]
  5. Maryland Psychiatric Research Center
  6. AstraZeneca
  7. Janssen-Cilag
  8. EliLilly
  9. Pfizer
  10. SanofiAventis

向作者/读者索取更多资源

Objective: The metabolic side effects of second-generation antipsychotics (SGA) are serious and have not been compared head to head in a meta-analysis. We conducted a meta-analysis of studies comparing the metabolic side effects of the following SGAs head-to-head: amisulpride, aripiprazole, clozapine, olanzapine, quetiapine, risperidone, sertindole, ziprasidone, zotepine. Method: We searched the register of the Cochrane schizophrenia group (last search May 2007), supplemented by MEDLINE and EMBASE (last search January 2009) for randomized, blinded studies comparing the above mentioned SGA in the treatment of schizophrenia or related disorders. At least three reviewers extracted the data independently. The primary outcome was weight change. We also assessed changes of cholesterol and glucose. The results were combined in a meta-analysis. Results: We included 48 studies with 105 relevant arms. Olanzapine produced more weight gain than all other second-generation antipsychotics except for clozapine where no difference was found. Clozapine produced more weight gain than risperidone, risperidone more than amisulpride, and sertindole more than risperidone. Olanzapine produced more cholesterol increase than aripiprazole, risperidone and ziprasidone. (No differences with amisulpride, clozapine and quetiapine were found). Quetiapine produced more cholesterol increase than risperidone and ziprasidone. Olanzapine produced more increase in glucose than amisulpride, aripiprazole, quetiapine, risperidone and ziprasidone: no difference was found with clozapine. Conclusions: Some SGAs lead to substantially more metabolic side effects than other SGAs. When choosing an SGA for an individual patient these side effects with their potential cause of secondary diseases must be weighed against efficacy and characteristics of the individual patient. (C) 2010 Elsevier B.V. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据